1594 related articles for article (PubMed ID: 27041995)
21. Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines.
Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Alsaidan YSM; Alfaiz SA; Haque A; Az A; Alhazzani K
Chem Phys Lipids; 2020 Nov; 233():105003. PubMed ID: 33096096
[TBL] [Abstract][Full Text] [Related]
22. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system.
Chalikwar SS; Belgamwar VS; Talele VR; Surana SJ; Patil MU
Colloids Surf B Biointerfaces; 2012 Sep; 97():109-16. PubMed ID: 22609590
[TBL] [Abstract][Full Text] [Related]
23. Topical Amphotericin B solid lipid nanoparticles: Design and development.
Butani D; Yewale C; Misra A
Colloids Surf B Biointerfaces; 2016 Mar; 139():17-24. PubMed ID: 26700229
[TBL] [Abstract][Full Text] [Related]
24. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
Ther Deliv; 2010 Jul; 1(1):63-73. PubMed ID: 22816120
[TBL] [Abstract][Full Text] [Related]
25. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
26. Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles.
Kumar M; Sharma G; Singla D; Singh S; Kakkar V; Gulati JS; Kaur IP
Pharm Nanotechnol; 2020; 8(6):495-510. PubMed ID: 33115399
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
28. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
Garg A; Singh S
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
[TBL] [Abstract][Full Text] [Related]
29. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles.
Vivek K; Reddy H; Murthy RS
AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544
[TBL] [Abstract][Full Text] [Related]
30. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
Jain A; Sharma T; Kumar R; Katare OP; Singh B
Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
[TBL] [Abstract][Full Text] [Related]
31. Solid lipid nanoparticles as delivery systems for Gambogenic acid.
Huang X; Chen YJ; Peng DY; Li QL; Wang XS; Wang DL; Chen WD
Colloids Surf B Biointerfaces; 2013 Feb; 102():391-7. PubMed ID: 23010123
[TBL] [Abstract][Full Text] [Related]
32. Characterization and stability of nanostructured lipid carriers as drug delivery system.
Abbasalipourkabir R; Salehzadeh A; Abdullah R
Pak J Biol Sci; 2012 Feb; 15(3):141-6. PubMed ID: 22866544
[TBL] [Abstract][Full Text] [Related]
33. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.
Silva AC; Kumar A; Wild W; Ferreira D; Santos D; Forbes B
Int J Pharm; 2012 Oct; 436(1-2):798-805. PubMed ID: 22867992
[TBL] [Abstract][Full Text] [Related]
34. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
Song A; Zhang X; Li Y; Mao X; Han F
Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
[TBL] [Abstract][Full Text] [Related]
35. Alpha-lipoic acid-stearylamine conjugate-based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in-vivo pharmacokinetic and hepatotoxicity study.
Dhaundiyal A; Jena SK; Samal SK; Sonvane B; Chand M; Sangamwar AT
J Pharm Pharmacol; 2016 Dec; 68(12):1535-1550. PubMed ID: 27709612
[TBL] [Abstract][Full Text] [Related]
36. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin.
Abul Kalam M; Sultana Y; Ali A; Aqil M; Mishra AK; Aljuffali IA; Alshamsan A
J Biomed Mater Res A; 2013 Jun; 101(6):1813-27. PubMed ID: 23255511
[TBL] [Abstract][Full Text] [Related]
37. Solid lipid nanoparticles for the controlled delivery of poorly water soluble non-steroidal anti-inflammatory drugs.
Kumar R; Singh A; Garg N; Siril PF
Ultrason Sonochem; 2018 Jan; 40(Pt A):686-696. PubMed ID: 28946474
[TBL] [Abstract][Full Text] [Related]
38. Primary Studies on Construction and Evaluation of Ion-Sensitive in situ Gel Loaded with Paeonol-Solid Lipid Nanoparticles for Intranasal Drug Delivery.
Sun Y; Li L; Xie H; Wang Y; Gao S; Zhang L; Bo F; Yang S; Feng A
Int J Nanomedicine; 2020; 15():3137-3160. PubMed ID: 32440115
[TBL] [Abstract][Full Text] [Related]
39. Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats.
Wang H; Wang H; Yang W; Yu M; Sun S; Xie B
AAPS PharmSciTech; 2018 Feb; 19(2):761-768. PubMed ID: 28983849
[TBL] [Abstract][Full Text] [Related]
40. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery.
Dong Z; Xie S; Zhu L; Wang Y; Wang X; Zhou W
Drug Deliv; 2011 Aug; 18(6):441-50. PubMed ID: 21554156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
